Objectif
The opportunity to focus on the production of biopharmaceuticals is often taken from SMEs since huge amount of resources is required for the development of high-producer cell lines. We envision that our parental cell factories will increase the efficiency of cell line engineering and will effectively reduce the time-to-market for mammalian cell-based products. It allows SMEs to leverage their traditional strengths of adaptability and creativity, and to develop novel products for biotechnology industries.
Champ scientifique
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
ICOSAGEN CELL FACTORY OU
Contribution nette de l'UE
€ 50 000,00
Adresse
EERIKA TEE 1
61713 Kambja Vald
Estonie
61713 Kambja Vald
Estonie
PME
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
Oui
Région
Eesti
Eesti
Lõuna-Eesti
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Liens
Coût total
€ 71 429,00